LY-367,265
LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT2A receptor, and also a selective serotonin reuptake inhibitor (SSRI). It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.[1][2][3]
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C24H25FN4O2S |
Molar mass | 452.54 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Pullar, I. A.; Carney, S. L.; Colvin, E. M.; Lucaites, V. L.; Nelson, D. L.; Wedley, S. (2000). "LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: A comparison with the antidepressant, nefazodone". European Journal of Pharmacology. 407 (1–2): 39–46. doi:10.1016/S0014-2999(00)00728-7. PMID 11050288.
- Wang, S. J. (2005). "Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex". Synapse. 55 (3): 156–163. doi:10.1002/syn.20104. PMID 15602751.
- Durmus, N.; Bagcivan, A.; Gursoy, S.; Altun, I.; Durmus, E. (2011). "Effects of fluoxetine and LY 365265 on tolerance to the analgesic effect of morphine in rats". Acta Physiologica Hungarica. 98 (2): 205–213. doi:10.1556/APhysiol.98.2011.2.12. PMID 21616779.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.